• Rady Children's Hospital-San Diego becomes first U.S. customer
• NorthStar iMR system marks the start of U.S. commercial launch
• Imricor Cardiovascular opens a new market in the U.S.

Imricor Medical Systems, Inc. (ASX: IMR) has officially commenced its U.S. commercial operations. Rady Children's Hospital-San Diego has purchased Imricor's NorthStar interventional magnetic resonance (iMR) mapping and guidance system, marking the first commercial U.S. hospital customer. This follows the U.S. FDA 510(k) clearances of NorthStar and the Vision-MR Diagnostic Catheter, as well as pediatric label expansions. Rady Children's will launch a NorthStar-guided iMR cardiac catheterization program, aiming to expand into radiation-free electrophysiology and ablation procedures. Imricor Cardiovascular, a new vertical, harnesses the superior imaging power of MR for cardiac catheterization, targeting over 250 children's hospitals and 2,000 adult hospitals in the U.S. Several additional U.S. hospitals are in the final stages of purchasing NorthStar, with sales expected in the coming weeks. Revenue from these sales is projected to exceed the aggregate full-year revenue from the European business in 2025. Imricor is expanding its U.S. commercial team to support growth.

Revenue from NorthStar sales expected to exceed full-year European business revenue in 2025

Imricor plans to expand its sales organization and introduce new devices and applications within the Cardiovascular business over time.